Skip to main content

Table 4 Altered lipids in lung cancer and potential biomarkers in QDLS and QDYD syndromes

From: Integrated DIA proteomics and lipidomics analysis on non-small cell lung cancer patients with TCM syndromes

Metabolite

QDLS/H

QDYD/H

QDLS/QDYD

p

FC

p

FC

p

FC

LPC (18:2)

0.002

↓ 0.42

↓ 0.55

0.005

↓ 0.77

LPE (16:0)

↑ 1.72

< 0.001

↑ 4.31

0.013

↓ 0.40

PC (16:0/17:1)

0.048

↑ 2.59

0.01

↑ 1.64

↑ 1.58

PC (16:0/18:2)

↑ 1.27

< 0.001

↑ 2.45

0.018

↓ 0.52

PC (17:0/18:1)

0.017

↑ 1.88

0.045

↑ 1.54

↑ 1.21

PC (18:1/16:0)

0.006

↑ 1.70

< 0.001

↑ 1.91

↓ 0.89

PC (P-18:0/20:4)

< 0.001

↑ 9.72

0.002

↑ 38.44

↓ 0.25

PC (18:2/18:0)

< 0.001

↑ 2.01

< 0.001

↑ 1.93

↑ 1.04

PC (18:1/18:0)

< 0.001

↑ 1.90

< 0.001

↑ 1.94

↓ 0.98

PC (18:1/20:4)

< 0.001

↑ 3.88

< 0.001

↑ 3.55

↑ 1.09

PC (20:4/18:0)

< 0.001

↑ 3.06

< 0.001

↑ 2.56

↑ 1.19

PC (20:3/18:0)

< 0.001

↑ 1.60

< 0.001

↑ 1.62

↓ 0.99

PE (16:0/18:2)

0.014

↑ 2.43

< 0.001

↑ 2.80

↓ 0.87

PE (16:0/20:4)

0.01

↑ 2.05

< 0.001

↑ 3.15

↓ 0.65

SM (d18:1/16:0)

0.002

↓ 0.74

< 0.001

↓ 0.72

↑ 1.03

SM (d18:1/22:0)

0.007

↓ 0.50

0.042

↓ 0.64

↓ 0.78

SM (d18:1/23:0)

0.026

↓ 0.52

0.035

↓ 0.58

↓ 0.90

SM (d18:1/24:0)

0.013

↓ 0.44

0.045

↓ 0.55

↓ 0.8

SM (d39:1)

0.001

↓ 0.09

0.001

↓ 0.10

↓ 0.9

SM (d18:2/24:1)

< 0.001

↑ 2.49

< 0.001

↑ 2.30

↑ 1.08

SM (d41:2)

< 0.001

↓ 0.22

0.006

↓ 0.38

↓ 0.58

DG (16:0/18:3)

< 0.001

↑ 1.84

0.002

↑ 1.72

↑ 1.07

DG (18:0/18:0)

< 0.001

↑ 2.00

< 0.001

↑ 1.83

↑ 1.09

DG (16:0/18:0)

< 0.001

↑ 2.16

< 0.001

↑ 1.93

↑ 1.12

DG (18:1/18:1)

< 0.001

↑ 6.03

0.002

↑ 6.41

↓ 0.94

TG (15:0/16:0/18:1)

0.003

↑ 4.15

0.003

↑ 2.95

↑ 1.41

TG (16:0/18:1/18:3)

< 0.001

↑ 2.51

< 0.001

↑ 2.55

↓ 0.98

TG (16:0/17:1/18:1)

0.016

↑ 2.98

0.002

↑ 2.96

↑ 1.01

TG (16:0/17:0/18:1)

0.029

↑ 3.37

0.003

↑ 2.68

↑ 1.26

TG (16:0/18:1/20:4)

< 0.001

↑ 2.38

< 0.001

↑ 2.52

↓ 0.94

TG (16:0/18:1/20:3)

< 0.001

↑ 4.39

< 0.001

↑ 5.56

↓ 0.79

TG (17:0/18:1/18:2)

0.029

↑ 2.75

0.003

↑ 2.21

↑ 1.24

TG (18:0/18:1/18:1)

< 0.001

↑ 3.89

< 0.001

↑ 4.76

↓ 0.82

TG (16:0/18:1/22:1)

0.036

↑ 2.12

0.01

↑ 2.46

↓ 0.86

TG (18:1/18:1/22:4)

0.003

↑ 3.54

< 0.001

↑ 3.22

↑ 1.09

Cer (d18:1/24:1)

0.024

↑ 2.29

< 0.001

↑ 2.16

↑ 1.06

Cholesterol

< 0.001

↑ 2.18

< 0.001

↑ 1.99

↑ 1.10

LPC (14:0)

0.004

↓ 0.46

PC (O-16:0/16:0)

0.018

↑ 1.65

PC (O-16:0/20:4)

0.042

↓ 0.74

PC(P-20:0/20:4)

0.045

↑ 1.51

SM (d18:2/22:0)

0.009

↓ 0.59

SM (d38:1)

< 0.001

↓ 0.22

SM (d18:2/25:0)

0.019

↑ 2.52

TG (15:0/16:0/18:2)

0.039

↑ 2.22

TG (16:0/18:2/18:3)

0.005

↑ 2.31

TG (16:0/18:1/18:2)

< 0.001

↑ 3.98

TG (14:0/18:2/22:6)

0.029

↓ 0.33

TG (17:0/18:0/18:1)

0.041

↑ 14.99

TG (18:2/18:2/18:3)

0.031

↓ 0.37

TG (18:1/18:1/20:4)

< 0.001

↑ 2.42

TG (18:2/18:2/20:5)

0.041

↓ 0.37

TG (18:0/18:1/20:3)

0.019

↑ 1.75

LPC (16:1)

0.024

↓ 0.64

PC (14:0/18:2)

0.003

↓ 0.47

PC (16:0/20:3)

< 0.001

↑ 1.89

PC (16:0/22:6)

< 0.001

↑ 1.73

PE (16:0/22:6)

< 0.001

↑ 3.32

PE (18:0/20:4)

0.007

↑ 2.31

SM (d36:0)

0.048

↑ 2.03

SM (d40:2)

0.003

↓ 0.36

DG (18:1/18:2)

0.009

↑ 1.89

TG (17:0/18:1/18:1)

0.002

↑ 2.55

TG (18:1/18:1/20:1)

0.004

↑ 2.27

TG (18:1/18:1/22:5)

0.011

↑ 2.15

TG (18:1/18:1/22:0)

0.002

↑ 4.63

  1. QDLS for whom suffered Qi deficiency of lung-spleen syndrome of lung cancer; QDYD for whom suffered Qi deficiency and Yin deficiency syndrome of lung cancer; FC the ratio of ion intensity for potential biomarkers from patients or healthy volunteers by using the developed UHPLC-Q-TOF/MS method